名稱 | EGFR WT (EGF Dependent)/BaF3 |
型號(hào) | CBP73166 |
報(bào)價(jià) | ![]() |
特點(diǎn) | EGFR WT (EGF Dependent)/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- EGFR 20外顯子突變類型標(biāo)準(zhǔn)品
- 上海生科院發(fā)現(xiàn)PKM2抑制細(xì)胞凋亡的新機(jī)制
- 免疫療法對(duì)一類常見白血病顯療效
- JCI:中山大學(xué)科學(xué)家找到可能*治愈常見白血病的新靶點(diǎn)
- 你知道乳酸對(duì)腫瘤細(xì)胞有哪些作用嗎?
- 【產(chǎn)品推介】胰高血糖素受體藥物細(xì)胞篩選模型
- 剖析正常細(xì)胞是如何成長(zhǎng)為腫瘤細(xì)胞的
- PLoS ONE:科學(xué)家發(fā)現(xiàn)癌癥轉(zhuǎn)移的新線索
- 【產(chǎn)品推介】MSI標(biāo)準(zhǔn)品
- 選擇進(jìn)口的細(xì)胞株這幾點(diǎn)千萬不能忘!
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73166EGFR WT (EGF Dependent)/BaF3

- 詳細(xì)內(nèi)容
CBP73166 | |
I. Introduction | |
Cell Line Name: | EGFR WT (EGF Dependent)/BaF3 |
Host Cell: | BA/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+100ng/ml EGF |
Mycoplasma Status: | Negative |
II.Background | |
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors. | |
III. Representative Data | |
1.WB of EGFR WT (EGF Dependent)/BaF3 | |
2. Anti-proliferation assay | |
Figure 2. CTG Proliferation Assay of EGFR WT(EGF Dependent) BaF3 cells (C16). |